Aumento della captazione del radioiodio indotto da selumetinib in pazienti con cancro della tiroide
By A. Ho, R. Grewal, R. Leboeuf, E. Sherman, D. Pfister, D. Deandreis, K. S. Pentlow, P. Zanzonico, S. Haque, S. Gavane and 8 more. L Endocrinologo, 2013
610 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/e6c21034279ff02c6ddf08e00a61224abb69699e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014, result): “This view is supported by recent data suggesting differential response to a MEK inhibitor related to thyroid cancer genotype (Ho et al., 2013).”
- The MAPK pathway across different malignancies: A new perspective (2014, background): “Mutations were detected in 7 of the 8 patient treated; responses were reported in 4 patients who had neuroblastoma RAS viral oncogene homolog (NRAS) mutations and in 1 patient who had a BRAF mutation.(55) Docetaxel with or without selumetinib was studied in a randomized phase 2 trial of 87 patients ”
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “The selective kinase inhibitors dabrafenib [81], vemurafenib [82] and selumetinib [83] can reportedly restore RAI uptake and tumour responses in selected patients, especially in those with small tumour burden and low progression rate.”
- Biologic and Clinical Perspectives on Thyroid Cancer (2016, neutral): “Adapted, with permission, from Ho et al.(11)”